Lipocine Inc., of Salt Lake City, said the FDA granted orphan status to LPCN 1107, its oral hydroxyprogesterone caproate product candidate, a potential treatment for the prevention of preterm birth. Lipocine previously reported positive phase Ib top-line data with LPCN 1107 in pregnant women.